Several biomarkers have been proposed, including the tumor mutation burden (TMB) (6), the neoantigens (7, 8), the overexpression of targeting genes such as PD-L1 (9, 10), and the amount and composition of the tumor-infiltrating immune cells (11, 12). Here, CD274 is linked to neoplasm.